Chemical component analysis of volatile oil in drug pair Herba Ephedrae-Ramulus Cinnamomi by GC-MS and CRM

Active volatile components in drug pair(DP)Herba Ephedrae-Ramulus Cinnamomi(HE-RC),single drug HE and RC were analyzed by gas chromatography/mass spectrometry(GC/MS),chemometric resolution method(CRM)and overall volume integration.By means of CRM,the two-dimensional data obtained from GC-MS instruments were resolved into a pure chromatogram and a mass spectrum of each chemical compound.In total,97,62,and 78 volatile chemical components in volatile oil of HE,RC,and DP HE-RC,were respectively determined qualitatively and quantitatively,accounting for 90.08%,91.62%,and 89.76% total contents of volatile oil of HE,RC,and DP HE-RC respectively.It is further demonstrated that the numbers of volatile components of DP HE-RC are almost the sum of those of two single drugs,but some relative contents of them are changed.Some new components,such as 1,6-dimethylhepta-1,3,5-triene,tetracyclo[4.2.1.1(2,5).0(9,10)]deca-3,7-diene,globulol and(E,E)-6,10,14-trimethyl-5,9,13-pentadecatrien-2-one are found in DP HE-RC because of chemical reactions and physical changes during decoction.

Study on the mechanism of“Salvia chinensis and Radix Ranunculi Ternati”drug pair in the treatment of lung cancer

Objective:To explore the molecular biological mechanism of the"salvia chinensis and radix ranunculi ternati"drug pair in the treatment of lung cancer based on network pharmacology.Methods:Searching the TCMSP database and previous literatures to screen the active compounds which resist lung cancer activity in salvia chinensis and radix ranunculi ternati.The candidate compounds were unified in the DrugBank to find the corresponding drug targets which were corrected to the standard gene names by the UniProt database.The Swiss Target Prediction platform was used to predict other targets.Searching GeneCards,OMIM and DrugBank to obtain genes related to lung cancer.After taking the intersection,the candidate gene target of drug pair in the treatment of lung cancer could be obtained.The"herbs-compounds-targets-disease"network was bulit with Cytoscape,and the PPI network was bulit on the STRING platform while the core network nodes were screened.GO and KEGG analysis on candidate genes was implemented through Metacape platform,and a"pathways-targets"network was bulit to further screen key genes.Results:A total of 16 active compounds in salvia chinensis,18 active compounds in radix ranunculi ternati,164 candidate targets,2443 GO functions and 170 KEGG pathways was obtained.Conclusion:The effective compounds of"salvia chinensis and radix ranunculi ternati"drug pair in the treatment of lung cancer are quercetin,ursolic acid,β-sitosterol and caffeic acid.The key targets are MAPK1,AKT1,PIK3R1,RAF1 and EGFR.GO functions mainly include cytokines,oxidative stress,plasma membrane transmission,protein kinase binding and activity,apoptosis.KEGG could directly regulate pathways in cancer,non-small cells lung cancer pathway and small cell lung cancer pathway.KEGG also involves EGFR tyrosine kinase inhibitor resistance,IL-17,TNF,PI3K-AKT signaling pathway and apoptosis.This study reveals the molecular biological mechanism of"salvia chinensis and radix ranunculi ternati"drug pair in the treatment of lung cancer.It is reasoned that its potential targets affect multiple signaling pathways and ultimately resist the proliferation,differentiation,invasion,metastasis and promote apoptosis of lung cancer cells.Evidence for further experimental study is provided by this study.

Network pharmacology study of drug pair Tubeimu-Zhebeimu in the treatment of breast cancer

Objective:Breast cancer is a malignant tumor endangering women’s safety and health.Clinical medication experience and related studies show that the drug pairs Tubeimu-Zhebeimu has an excellent therapeutic effect on patients with breast cancer,but its treatment mechanism is unclear.In this study,network pharmacology and molecular docking were used to analyze and explore the mechanism of“Tubeimu-Zhebeimu”in treating breast cancer.Methods:Traditional Chinese Medicine Database and Analysis Platform were used to retrieve the chemical constituents of Tubeimu and Zhebeimu,and the relevant targets were predicted through the Swiss Target Prediction Database.Searching the Gene cards,Therapeutic Target Database and Disgenet Database with the keywords“breast cancer”,“mammary cancer”and“mammary adenocarcinoma”obtain disease-related targets.We intersect the disease target with the drug target to obtain the potential drug therapy target.Then the data was imported into Cytoscape 3.9.1 software to construct a compound network of“Disease-Target-Component-Drug”,and the network.Subsequently,using the String Database a“protein-protein interaction network”was constructed and imported into Cytoscape 3.9.1 software for structural optimization and network topology analysis.DAVID was used for Gene Ontolog function enrichment and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment analyses,and the results were visualized.The core targets were molecularly docked through AutoDockTools-1.5.6 software and Auto Dock Vina 1.1.2 software.Results:The results showed that the 20 active ingredients in the“Tubeimu-Zhebeimu”includingβ-sitosterol,Chaksine,saponins,and peimuocinine,can treat breast cancer through 139 potential targets including AKT1,AR,TP53,ESR1.Conclusion:The specific mechanism of the drug pairs Tubeimu-Zhebeimu treating breast cancer may be controlling human hormone levels,inducing cell apoptosis,and participating in the P53 protein signaling pathway and PI3K/Akt/mTOR signaling pathway.

Analysis on the Medication Law of Drug Pair Acorus Tatarinowii-Polygala Tenuifolia Based on the Dictionary of Traditional Chinese Medicine Prescriptions

Objective:Using data mining method to dig and sort out the prescriptions with Acorus tatarinowiiPolygala tenuifolia drug pair,and summarize the medication characteristics and compatibility of their prescriptions after preliminary screening.Methods:By searching the Dictionary of Traditional Chinese Medicine Prescriptions,a standardized database of prescriptions was established,and the properties,tastes and meridian tropism of prescriptions were classified,and the indications of prescriptions and core combinations of traditional Chinese medicines were analyzed.Results:178 prescriptions were collected,of which 210 were related.Most of the drugs were warm in nature and sweet in taste,and mainly return to the heart and kidney meridians.Under the same confidence and different support,the core drug combination for treating brain diseases was Acorus tatarinowiiPolygala tenuifolia-Ginseng,and the core drug combination for treating asthenia was Acorus tatarinowii-Poria cocos-Rehmannia glutinosa-Polygala tenuifolia.Conclusion:The compatibility characteristics of the prescriptions containing Acorus Tatarinowii and Polygala tenuifolia in the Dictionary of Traditional Chinese Medicine Prescriptions are remarkable,which provides reference for scientific guidance of clinical rational drug use and basic research of prescriptions containing Acorus tatarinowii and Polygala tenuifolia.

Amplifying protection against acute lung injury:Targeting both inflammasome and cGAS-STING pathway by Lonicerae Japonicae Flos-Forsythiae Fructus drug pair

Objective:Acute lung injury(ALI)is characterized by inflammation and currently lacks an efficacious pharmacological intervention.The medicine combination of Lonicerae Japonicae Flos(LJF)and Forsythiae Fructus(FF)demonstrates combined properties in its anti-infective,anti-inflammatory,and therapeutic effects,particularly in alleviating respiratory symptoms.In previous studies,Chinese medicine has shown promising efficacy in lipopolysaccharides(LPS)-induced ALI.However,there have been no reports of LJF and FF pairing for lung injury.The aim of this study is to compare the efficacy of herb pair Lonicerae Japonicae Flos-Forsythiae Fructus(LF)with LJF or FF alone in the treatment of ALI,and to explore whether LJF and FF have a combined effect in the treatment of lung injury,along with the underlying mechanism involved.Methods:A total of 36 mice were divided into six groups(control,model,LJF,FF,LF,dexamethasone)based on the treatments they received after undergoing sham-operation/LPS tracheal instillation.H&E staining and pulmonary edema indexes were used to evaluate lung injury severity.Alveolar exudate cells(AECs)were counted based on cell count in bronchoalveolar lavage fluid(BALF),and neutrophil percentage in BALF was measured using flow cytometry.Myeloperoxidase(MPO)activity in BALF was measured using enzyme-linked immunosorbent assay(ELISA),while the production of IL-1β,TNF-α,and IL-6 in the lung and secretion level of them in BALF were detected by quantitative polymerase chain reaction(qPCR)and ELISA.The effect of LJF,FF,and LF on the expression of Caspase-1 and IL-1βproteins in bone marrow derived macrophages(BMDMs)supernatant was assessed using Western blot method under various inflammasome activation conditions.In addition,the concentration of IL-1βand changes in lactatedehydrogenase(LDH)release levels in BMDMs supernatant after LJF,FF,and LF administration,respectively,were measured using ELISA.Furthermore,the effects of LJF,FF and LF on STING and IRF3 phosphorylation in BMDMs were detected by Western blot,and the mRNA changes of IFN-β,TNF-α,IL-6 and CXCL10 in BMDMs were detected by qPCR.Results:LF significantly attenuated the damage to alveolar structures,pulmonary hemorrhage,and infiltration of inflammatory cells induced by LPS.This was evidenced by a decrease in lung index score and wet/dry weight ratio.Treatment with LF significantly reduced the total number of neutrophil infiltration by 75%as well as MPO activity by 88%.The efficacy of LF in reducing inflammatory factors IL-1β,TNF-α,and IL-6 in the lungs surpasses that of LJF or FF,approaching the effectiveness of dexamethasone.In BMDMs,the co-administration of 0.2 mg/mL of LJF and FF demonstrated superior inhibitory effects on the expression of nigericin-stimulated Caspase-1 and IL-1β,as well as the release levels of LDH,compared to individual treatments.Similarly,the combination of 0.5 mg/mL LJF and FF could better inhibit the phosphorylation levels of STING and IRF3 and the production of IFN-β,TNF-α,IL-6,and CXCL10 in response to ISD stimulation.Conclusion:The combination of LJF and FF increases the therapeutic effect on LPS-induced ALI,which may be mechanistically related to the combined effect inhibition of cyclic-GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)and NOD-like receptor family protein 3(NLRP3)inflammasomes pathways by LJF and FF.Our study provides new medicine candidates for the clinical treatment of ALI.

Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs

The COVID-19 pandemic has resulted in excess deaths worldwide.Conventional antiviral medicines have been used to relieve the symptoms,with limited therapeutic effect.In contrast,Lianhua Qingwen Capsule is reported to exert remarkable anti-COVID-19 effect.The current review aims to:1)uncover the main pharmacological actions of Lianhua Qingwen Capsule for managing COVID-19;2)verify the bioactive ingredients and pharmacological actions of Lianhua Qingwen Capsule by network analysis;3)investigate the compatibility effect of major botanical drug pairs in Lianhua Qingwen Capsule;and 4)clarify the clinical evidence and safety of the combined therapy of Lianhua Qingwen Capsule and conventional drugs.Numerous bioactive ingredients in Lianhu Qingwen,such as quercetin,naringenin,β-sitosterol,luteolin,and stigmasterol,were identified to target host cytokines,and to regulate the immune defence in response to COVID-19.Genes including androgen receptor(AR),myeloperoxidase(MPO),epidermal growth factor receptor(EGFR),insulin(INS),and aryl hydrocarbon receptor(AHR)were found to be significantly involved in the pharmacological actions of Lianhua Qingwen Capsule against COVID-19.Four botanical drug pairs in Lianhua Qingwen Capsule were shown to have synergistic effect for the treatment of COVID-19.Clinical studies demonstrated the medicinal effect of the combined use of Lianhua Qingwen Capsule and conventional drugs against COVID-19.In conclusion,the four main pharmacological mechanisms of Lianhua Qingwen Capsule for managing COVID-19 are revealed.Therapeutic effect has been noted against COVID-19 in Lianhua Qingwen Capsule.

Efficacy of an Yinyanghuo(Herba Epimedii Brevicornus)-Xianmao(Rhizoma Curculiginis)drug pair in a rat model of polycystic ovary syndrome

OBJECTIVE:To identify active compounds in an Yinyanghuo(Herba Epimedii Brevicornus)-Xianmao(Rhizoma Curculiginis)drug pair(ECD)and investigate its efficacy on polycystic ovary syndrome(PCOS),and its possible mechanism in a rat model of PCOS.METHODS:A network pharmacology approach involving a characteristic drug assessment,active compound and target prediction,PCOS gene collection as well as network analysis was employed.The ovary morphology after treatment was observed using an animal model and western blotting and real-time PCR were used to verify AKT1 as the molecular target.RESULTS:Six networks were constructed,an active compound-target network for the ECD(C-T network),a drug-target network(D-T network),a related genes network,a targets interaction network,a key genes interaction network,and a gene-pathway network.A total of 41 compounds and 261 targets were identified for the ECD,232 PCOS-related genes,31 cogenes,and 14 pathways.These pathways may be involved in the efficacy of ECD on PCOS.The proteins most involved in the signal pathways for all targets were AKT1,IL6,INSR,ESR,and GSK3B.The AKT1 target was selected for experimental verification.Based on the Western blot and real-time PCR results,the expression of AKT1 in the PCOS model varied after treatment with ECD.CONCLUSIONS:Our findings suggest that the ECD can reverse the negative morphological changes in ovarian tissue that occur in model rats of PCOS.AKT1 may be a key mediator of the observed ability of the ECD to protect against PCOS in the model rats.

Mechanism of'Invigorating Qi and Promoting Blood Circulation'Drug Pair Ginseng-Danshen on Treatment of Ischemic Heart Disease Based on Network Pharmacology

Objective:Using network pharmacology to explore the mechanism of the'invigorating qi and promoting blood circulation'drug pair Ginseng-Danshen(Salvia miltiorrhiza)on treatment of ischemic heart disease(IHD).Methods:The chemical constituents of ginseng and Danshen drug pair were identified by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP),and the potential targets of the pair were identified.The pharmacodynamics of the pair was analyzed using network pharmacology.The targets of IHD were identified by database screening.Using protein-protein interaction network,the interaction targets of Ginseng-Danshen on IHD were constructed.A"constituent-target-disease"interaction network was constructed using Cytoscape software,Gene Ontology(GO)term enrichment analysis and biological pathway enrichment analysis were carried out,and the mechanism of improving myocardial ischemia by the Ginseng-Danshen drug pair was investigated.Results:Seventeen active constituents and 53 targets were identified from ginseng,53 active constituents and 61 targets were identified from Danshen,and 32 protein targets were shared by ginseng and Danshen.Twenty GO terms were analyzed,including cytokine receptor binding,cytokine activity,heme binding,and antioxidant activity.Sixty Kyoto Encyclopedia of Genes and Genomes(KEGG)signaling pathways were analyzed,including phosphatidylinositol 3-kinase-serine-threonine kinase(PI3 K-AKT)signaling pathway,p53 signaling pathway,interleukin 17 signaling pathway,tumor necrosis factor signaling pathway,and the advanced glycation end product(AGE)-the receptor for AGE(RAGE)signaling pathway in diabetic complications.Conclusion:The specific mechanism of Ginseng-Danshen drug pair in treating IHD may be associated with improving the changes of metabolites inbody,inhibiting the production of peroxides,removing the endogenous oxygen free radicals,regulating the expression of inflammatory factors,reducing myocardial cell apoptosis and promoting vascular regeneration.

Mechanism of the Salvia miltiorrhiza-Codonopsis pilosula drug pair in the treatment of premature ovarian failure based on network pharmacology-molecular docking

Objective: Premature ovarian failure (POF) is a disease characterized by irregular menstruation and results in infertility which markedly affects the reproductive health of women. TheSalvia miltiorrhiza-Codonopsis pilosula drug pair is effective at treating POF;however, knowledge of the mechanisms ofS. miltiorrhiza-C. pilosula in the treatment of POF is lacking. Thus, we carried out network pharmacology and molecular docking to clarify the mechanisms of this drug pair.Methods: The core components and targets ofS. miltiorrhiza-C. pilosula were obtained using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database and UniProt database, and the disease targets related to POF were searched using different tools to obtain the overlapping target genes ofS. miltiorrhiza andC. pilosula. A protein interaction network of the intersection target was constructed using STRING database, and the network of "traditional Chinese medicine-active ingredient-intersection target-disease" and "pathways-targets" was constructed using Cytoscape 3.8.0. The DAVID online tool was also used to determine the gene ontology functions and Kyoto Encyclopedia of Genes and Genomes pathways associated with the intersection target genes. Finally, the binding ability of the drug to the active components and potential targets were predicted using molecular docking.Results: S. miltiorrhizae-C. pilosula had 72 active components, 128 targets, 3,775 POF targets, and 106 common targets. The potential targets were mainly related to the biological processes of DNA-binding transcription factor binding, RNA polymerase II-specific DNA-binding transcription factor binding, transcription factor activity, steroid receptor activity, and hypoxia response. Further, the Kyoto Encyclopedia of Genes and Genomes enrichment pathways included PI3K-Akt signaling pathway, apoptosis, interleukin (IL)-17 signaling pathway, relaxin signaling pathway, and other biological pathways.Conclusion(s): S. miltiorrhiza-C. pilosula can inhibit ovarian granulosa cell apoptosis and improve ovarian hemodynamics through multiple targets and multiple pathways and help treat POF.

益智仁-乌药药对调控PI3K/Akt/mTOR通路介导细胞自噬保护肾小球足细胞的作用机制研究

目的研究益智仁-乌药药对通过调控PI3K/Akt/mTOR信号通路促进足细胞自噬治疗糖尿病肾病(Diabetic Nephropathy,DN)的作用。方法60只造模成功的C57BL/KSJ-db/db(以下简称db/db)小鼠随机分为模型组、二甲双胍组、缬沙坦组、益智仁-乌药药对(低、中、高剂量)组,每组10只;另取10只C57BL/KSJ-db/m(以下简称db/m)小鼠为正常组,正常组和模型组给予生理盐水,治疗组小鼠分别给予相应药物,给药8周后检测小鼠肾脏病理学改变,足细胞自噬体数量、结构及相关蛋白表达。结果与模型组相比,益智仁-乌药药对组可显著减轻糖尿病肾病小鼠肾小球基底膜增厚情况,增加足细胞自噬体数量,显著升高自噬相关蛋白表达(P<0.05),降低PI3K/Akt/mTOR信号通路相关蛋白的表达(P<0.05)。其中益智仁-乌药药对高剂量组各指标改善优于益智仁-乌药低、中剂量组。结论益智仁-乌药药对通过抑制PI3K/Akt/mTOR信号通路激活,提高足细胞自噬水平,减轻足细胞损伤,发挥治疗糖尿病肾病的作用。

谢晶日基于因机论治对慢性萎缩性胃炎的药对选用

谢晶日教授从事临床诊疗工作四十余载,学识深邃,医术精湛,立足因机论治,在慢性萎缩性胃炎的诊治中独树一帜。谢晶日教授认为慢性萎缩性胃炎发病与虚、滞、湿、热、瘀、毒联系密切,基本病机无外乎脾胃虚弱、肝郁气滞、气血失调、湿热内蕴、胃络瘀阻、邪毒互结。谢教授在治疗过程中,审病求因,紧扣病机,因机论治,精准选用药对,有效缓解慢性萎缩性胃炎的临床症状,延缓病程的进展,防止癌变的发生。

三七药对的研究进展

三七作为临床常用中药,在临床应用中有多种药对形式。围绕近年来基于网络药理学的三七药对、传统三七药对及三七药对配伍前后化学成分变化的实验研究进行归纳和总结,系统阐释三七药对在临床应用的作用机制和科学内涵,为进一步研究三七药对使用规律、配伍理论、临床应用等方面提供新的思路。

丹参-当归治疗缺血性脑卒中作用机制网络药理学研究

目的探讨丹参-当归治疗缺血性脑卒中(CIS)的潜在作用机制。方法通过中药系统药理学数据库与分析平台(TCMSP)、Swiss TargetPrediction数据库获取丹参和当归的活性成分及作用靶点,并通过检索PubMed、中国知网相关文献进行补充;通过GeneCards、人类孟德尔遗传数据库(OMIM)、DisGeNET数据库获取CIS的潜在靶点;将丹参-当归治疗CIS的共有靶点导入String 11.0平台,构建活性成分与疾病靶点蛋白的蛋白相互作用(PPI)网络,利用Cytoscape 3.8.2软件构建疾病-药物-活性成分-靶点可视化网络;将共有靶点导入DAVID数据库进行基因本体论(GO)功能富集和京都基因与基因组百科全书(KEGG)通路富集分析,并利用Cytoscape 3.8.2软件构建活性成分-核心靶点-通路网络;利用AutoDock软件对疾病-药物-活性成分-靶点网络中度值排名前6的核心靶点和活性成分进行分子对接验证。结果共检索到82种活性成分,其中丹参65个、当归17个,潜在作用靶点787个,疾病靶点671个,共有靶点76个。度值排名前6的活性成分为丹参醇B、丹参新醌D、木犀草素、阿魏酸、藁本内酯、丹参酮ⅡA,核心靶点为MAPK14,MAPK1,AKT1,PTGS2,EGFR,JAK2。共获得GO功能条目2545个,其中生物学过程2244个,细胞组成128个,分子功能173个,分别涉及对脂多糖的反应、膜筏、内肽酶活性等;KEGG信号通路152条,主要涉及PI3K-Akt信号通路、脂质和动脉粥样硬化、钙信号通路等。分子对接结果证明了6种活性成分与其相应核心靶点均有较好的结合活性。结论丹参-当归治疗CIS具有多成分-多靶点-多通路的调控特点,其作用机制可能与抗炎、抗氧化应激、抗神经细胞凋亡、调节自噬功能等有关。

治疗脾胃病的含救必应药对对溃疡性结肠炎的治疗作用

目的分析治疗脾胃病的含救必应药对对溃疡性结肠炎(UC)的治疗作用。方法(1)在中国知网数据库和万方数据知识服务平台中检索使用救必应治疗脾胃病的临床研究,收集其临床处方。应用数据挖掘技术分析治疗脾胃病的含救必应核心药对。(2)选择90只小鼠,将其随机分为正常组、模型组、救必应组及6组救必应药对组,每组10只。除正常组外,给予其余组小鼠饮用3%葡聚糖硫酸钠以建立UC模型,同时给予各给药组小鼠灌胃1.8 g/kg的相应药物,连续灌胃6 d,1次/d。在实验期间记录各组小鼠的一般症状,实验第7天观察其结肠外观、病理改变,检测其结肠组织Occludin蛋白、抗黏蛋白2(MUC2)、ATOH1蛋白的表达水平。结果(1)共获得6组含救必应的核心药对,分别为救必应-白芍、救必应-白术、救必应-茯苓、救必应-蒲公英、救必应-柴胡、救必应-党参。(2)与正常组比较,模型组小鼠的结肠长度缩短,体重下降率、疾病活动指数(DAI)及肺脏系数升高,结肠组织中MUC2、ATOH1和Occludin的蛋白表达水平降低(P<0.05)。与模型组相比,救必应-党参组小鼠体重下降率降低,救必应组、救必应-白芍组及救必应-党参组小鼠的结肠长度增加,救必应组、救必应-茯苓组及救必应-党参组小鼠的DAI降低,救必应组及救必应-白芍组小鼠的肺脏系数降低(P<0.05);救必应组及救必应-白芍组、救必应-柴胡组、救必应-党参组小鼠结肠组织黏膜下层水肿及炎症细胞浸润有所改善,救必应-白术组、救必应-茯苓组、救必应-蒲公英组小鼠结肠的黏液屏障损伤有所改善;救必应组MUC2、ATOH1和Occludin的蛋白表达水平上调,救必应-白术组、救必应-茯苓组、救必应-蒲公英组和救必应-党参组MUC2的蛋白表达水平上调,救必应-白芍能组ATOH1的蛋白表达水平上调,救必应-白术组Occludin的蛋白表达水平上调(P<0.05)。与救必应组相比,救必应-党参组的结肠长度增加,救必应-党参组及救必应-白芍药组对结肠病理改变的改善作用更为明显,救必应-白术组MUC2的蛋白表达水平更高(P<0.05)。结论救必应治疗脾胃病常用配伍药物为白芍、白术、茯苓、蒲公英、柴胡和党参。大多数含救必应药对可不同程度地改善UC小鼠模型的一般症状、病理表现及黏膜屏障蛋白的表达,其中,救必应-党参药对在改善结肠短缩及结肠病理改变方面均优于单用救必应,而救必应-白术药对在上调MUC2蛋白表达方面优于单用救必应。

基于七情配伍理论的补骨脂药对配伍规律研究进展

目的 基于中药七情配伍理论归纳补骨脂药对配伍规律,为补骨脂临床合理应用提供依据。方法 通过古籍与现代文献检索与分析,从相须相使、协同增效、相畏相杀、减毒降副,配伍禁忌三方面总结补骨脂配伍规律。结果 基于七情配伍理论探析补骨脂药对的配伍规律,补骨脂常用相须相使药对为肉豆蔻、蛇床子、小茴香、益智仁、肉桂、吴茱萸、巴戟天、杜仲、骨碎补、仙茅,常用相畏相杀药对为胡桃仁、生地黄、五味子、赤芍,相恶、相反禁忌药对有甘草、淫羊藿。结论 总结了常与补骨脂配伍的药对,为临床遣方用药提供思路。

张念志教授治疗甲状腺结节药对经验举隅

甲状腺结节属于中医“瘿病”的范畴,目前对甲状腺结节的诊疗多依靠FAN的结果,而FNA存在假阴性率,手术治疗也会造成血肿、感染等问题。中医药治疗甲状腺结节有着悠久的历史,可以避免手术造成的副作用,消除患者的恐惧心理,大量文献古籍记载了相关内容且经过临床实践,疗效甚佳。文章总结了张教授业医30余载,通过大量的实践经验及临床总结,详加辨证施治,着眼于甲状腺结节“气郁、血瘀、痰浊”的病机特点,采用或祛邪扶正的治疗原则,治疗甲状腺结节临床效果显著。

7576张含丹参-当归药对的门诊中药饮片处方回顾性分析

目的:了解江苏省中西医结合医院南部院区/南京市溧水区中医院(以下简称“该院”)含丹参-当归药对的门诊中药饮片处方情况,探究该药对的临床配伍应用规律,为该药对的合理使用提供参考。方法:采用回顾性分析方法,统计2020—2022年该院使用丹参-当归药对的7576张门诊中药饮片处方,对患者的性别、年龄、处方药味数、金额、疗程、涉及科室及病症、使用剂量、常用的配伍比例及配伍饮片等相关内容进行统计分析。结果:7576张含丹参-当归药对的门诊中药饮片处方中,女性患者处方数约为男性患者处方数的3.21倍(5776张vs.1800张),>30~40岁患者居多。单张处方的中药饮片味数多集中在16~20味,开具的疗程均<30 d。丹参的使用剂量为《中华人民共和国药典》规定的10~15 g的处方有6490张,占85.67%;当归的使用剂量为《中华人民共和国药典》规定的6~12 g的处方有6608张,占87.22%。处方数排序居前3位的科室依次为国医堂、妇科及脑病科,治疗的病证以冲任失调、心脾两虚及气滞血瘀证为主。单张处方中丹参用量大于等于当归用量,丹参与当归的配伍比例以1∶1为多,高频配伍饮片为茯苓、川芎、炒白芍。结论:基于处方用药分析,该院含丹参-当归药对的门诊中药饮片处方基本合理,为丹参-当归药对的使用剂量范围及配伍规律研究提供了数据支持,有利于促进临床合理用药。

基于组分中药理论的薏苡仁-知母药对治疗糖尿病患者的配伍特点

药对是源于中医传统经方或验方,依据中药配伍原则,能长期应用并指导临床实践的两味药物相对固定的配伍形式,具有协同增效或配伍减毒的作用。薏苡仁-知母为典型的清热滋阴药对,二者相辅相成,治疗阴虚热盛型糖尿病患者效果显著。其成分知母皂苷、知母多糖、芒果苷、薏苡仁多糖等对糖尿病均有较好的干预作用。现从中医理论及现代药理学研究等层面探究薏苡仁-知母药对治疗糖尿病的配伍特点,剖析主要活性成分的降糖作用和作用机制,为治疗糖尿病的新药研究提供理论基础。

苦参-黄柏药对的提取工艺研究

目的研究苦参-黄柏药对的提取工艺,为治疗肛肠疾病的新药开发提供参考依据。方法以苦参总碱(苦参碱+氧化苦参碱)含量、盐酸小檗碱含量、总黄酮含量及浸膏得率为评价指标,采用层次分析法-熵权法计算各指标权重系数,结合Box-Behnken设计-响应面法研究苦参-黄柏药对的最佳提取工艺并进行验证。结果苦参-黄柏药对的最优提取工艺为以12倍量58%乙醇浸泡30 min后提取2次,每次120 min。验证实验结果与预测值的相对误差为1.88%。结论所得提取工艺稳定、可行,可为苦参-黄柏药对的进一步应用与新药开发提供参考。

基于网络药理学及转录组分析的“白术-苍术”药对防治高脂血症作用机制研究

[目的]明确“白术-苍术”药对对高脂血症(hyperlipidemia,HLP)的防治作用,结合网络药理学分析,初步阐释其作用机制。[方法]采用高脂饲料喂养复制HLP大鼠模型,同时给予不同剂量的“白术-苍术”药对进行干预;实验期末比较各组大鼠血脂水平并观察肝组织脂质沉积情况。采用网络药理学预测“白术-苍术”药对治疗HLP的潜在活性成分及作用靶点,并进一步进行实验验证。[结果]“白术-苍术”药对对高脂饮食诱导的HLP具有良好的防治作用。网络药理学分析发现,“白术-苍术”所含3β-醋酸基白术酮、汉黄芩素、3β-乙酰氧基苍术酮等成分为其治疗HLP的潜在活性成分,过氧化物酶体增殖物激活受体(peroxisome proliferators-activated receptors,PPAR)信号通路相关PPARγ、脂肪酸结合蛋白4(fatty acid binding protein 4,FABP4)为其潜在调节通路和作用靶点。动物实验结果表明,“白术-苍术”能显著上调HLP模型大鼠PPARγ表达。[结论]“白术-苍术”药对防治高脂饮食诱导的HLP的作用与激活PPARγ信号通路有关。